A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.
Lameris R, Ruben JM, Iglesias-Guimarais V, de Jong M, Veth M, van de Bovenkamp FS, de Weerdt I, Kater AP, Zweegman S, Horbach S, Riedl T, Winograd B, Roovers RC, Adang AEP, de Gruijl TD, Parren PWHI, van der Vliet HJ.
Lameris R, et al. Among authors: veth m.
Cell Rep Med. 2023 Mar 21;4(3):100961. doi: 10.1016/j.xcrm.2023.100961. Epub 2023 Mar 2.
Cell Rep Med. 2023.
PMID: 36868236
Free PMC article.